Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial-Reference-Cited by-同舟云学术

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

Published:2011-11 Issue:9806 Volume:378 Page:1858-1867
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Récher Christian,Coiffier Bertrand,Haioun Corinne,Molina Thierry Jo,Fermé Christophe,Casasnovas Olivier,Thiéblemont Catherine,Bosly André,Laurent Guy,Morschhauser Franck,Ghesquières Hervé,Jardin Fabrice,Bologna Serge,Fruchart Christophe,Corront Bernadette,Gabarre Jean,Bonnet Christophe,Janvier Maud,Canioni Danielle,Jais Jean-Philippe,Salles Gilles,Tilly Hervé

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001;Morton;Blood,2006

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

3. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

4. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol,2006

5. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

Cited by 313 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic Population;2024-09-11

2. A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients;European Journal of Haematology;2024-09-10

3. MYC Rearrangement Prediction from LYSA Whole Slide Images in Large B-cell Lymphoma: A Multi-centric Validation of Self-supervised Deep Learning Models;Modern Pathology;2024-09

4. Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration;Leukemia;2024-08-16

5. The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma;Journal of Personalized Medicine;2024-06-21